Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With: polyneuropathy

  • Long-Term Outcome for Patients with CIDP

    In a careful meta-analysis of published series of treated patients with chronic inflammatory demyelinating polyneuropathy (CIDP), about one-half of patients achieved a good long-term remission with independent function and only about 8% were unable to walk independently.

  • What Is the Right Dose of Immunoglobulin to Treat CIDP?

    In this comparative trial of different doses of intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy, higher doses appeared to result in a higher percentage of patients who improved. However, there was no control group and there were many confounding issues that make it difficult to reach a definitive conclusion around optimal dosing.

  • Pyridoxine (B6) Toxicity in Chronic Idiopathic Axonal Polyneuropathy

    In a careful prospective collection of features of chronic idiopathic axonal neuropathy, with retrospective ascertainment of vitamin B6 levels in the blood, the investigators reported there was no significant correlation between the severity of neuropathy symptoms and plasma B6 levels.

  • What Is Focal CIDP?

    Chronic inflammatory demyelinating polyneuropathy (CIDP) usually is diagnosed in patients who have a generalized disorder. However, there are focal syndromes that have been observed and diagnosed under different names that meet many of the clinical and electrodiagnostic criteria of CIDP and may be referred to as “focal” CIDP.

  • Is it Chronic Inflammatory Demyelinating Polyneuropathy or Charcot-Marie-Tooth Disease?

    Charcot-Marie-Tooth disease may be confused with chronic inflammatory demyelinating polyneuropathy, resulting in inappropriate and hazardous treatments. Age at onset < 40 years, a family history of neuropathy, absence of nerve hypertrophy on magnetic resonance imaging, and poor response to intravenous immune globulin treatment should prompt a genetic evaluation.

  • Is it Guillain-Barré or Acute-onset CIDP?

    Acute inflammatory demyelinating polyneuropathy and acute-onset chronic inflammatory demyelinating polyneuropathy (CIDP) may present with identical clinical pictures and can be differentiated only with the passage of time. CIDP will have a slower course of progression and may involve relapses.

  • Anti-MAG Antibodies: Clinical and Therapeutic Aspects

    Anti-MAG antibody-associated neuropathy may present as many disorders, including small fiber neuropathy, sensorimotor neuropathy, Guillain-Barré-like syndrome, and multifocal motor neuropathy. Rituximab appears to be the best therapeutic option.

  • Polyneuropathy and Nutrition

    Other than the identification of a specific vitamin or essential element deficiency, overall nutritional status does not appear to play any role in the development of idiopathic neuropathies in adults.

  • Polyneuropathy in the Metabolic Syndrome

    The metabolic syndrome, independent of the diagnosis of diabetes, is associated with the development of polyneuropathy.